Research published in Journal of Affective Disorders

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Journal of Affective Disorders April 1, 2025 Angela T H Kwan, Moiz Lakhani, Kayla M Teopiz et al. 11 citations

To determine whether there is disproportionate reporting of hepatobiliary disorders in the United States (US) FDA Adverse Event Reporting System (FAERS) for individuals prescribed ketamine or esketamine. We identified Medical Dictionary for Regulatory Activities (MedDRA) terms in the FAERS related to hepatobiliary disorders. Formulations of ketamine and esketamine were evaluated for the...

DOI: 10.1016/j.jad.2025.01.054 Full text Esketamine Drug-induced liver injury Hepatobiliary disorders Hepatotoxicity +9

Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

Journal of Affective Disorders March 15, 2025 Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros et al. 24 citations

Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a...

DOI: 10.1016/j.jad.2024.12.036 Full text Depression Adrenocorticotropic hormone Corticotropin releasing factor Cortisol +4

Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.

Journal of Affective Disorders March 15, 2025 Kevin H. Yang, Wayne Kepner, Charles M Cleland et al. 19 citations

Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored. We analyzed data from the 2015-2022 National Survey on Drug Use and Health focusing on adults in the US. Trends in past-year ketamine use, overall and by depression status, were...

DOI: 10.1016/j.jad.2024.12.108 Full text Depression Nationally representative samples Ketamine-use-trends Mental-health-epidemiology +2

Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.

Journal of Affective Disorders March 15, 2025 Thomas D Meyer, Maya Ibrahim, Lauren N Vale et al. 6 citations

Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic...

DOI: 10.1016/j.jad.2024.12.044 Full text Psychedelic drugs Behavioral health care Depression research Bipolar disorder +7

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Journal of Affective Disorders March 1, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 35 citations

To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with...

DOI: 10.1016/j.jad.2024.12.061 Full text Magic mushrooms Treatment-resistant depression Psychedelics psilocybin Hallucinogens +8

Effect of continuous esketamine infusion on brain white matter microstructure in patients with major depression: A diffusion tensor imaging study.

Journal of Affective Disorders March 1, 2025 Xiang Liu, Zhipeng Wei, Lifeng Li et al. 12 citations

Esketamine has demonstrated acute antidepressant effects in patients with major depressive disorder (MDD). This study investigated whether these effects associate with reversible white matter fiber integrity recovery using diffusion imaging. Twenty patients with MDD and 20 healthy controls received 2-week esketamine treatment. Patients received 0.25 mg/kg intravenous esketamine. Emotional and...

DOI: 10.1016/j.jad.2024.12.002 Full text Major depressive disorder Mdd Antidepressants antidepressant medication Depression medication +5

Clinical indicators of the suicide crisis and response to ketamine.

Journal of Affective Disorders March 1, 2025 Elizabeth D. Ballard, Lucinda Neely, Laura Waldman et al. 4 citations

This analysis sought to identify potential clinical targets for the suicide crisis. Characteristics of a useful clinical target include elevation at the time of suicide crisis and responsiveness to rapid-acting interventions. Suicidal ideation (SI), depression, and hopelessness were hypothesized to meet these criteria. Participants were 118 adults across the continuum of suicide risk, including...

DOI: 10.1016/j.jad.2024.11.080 Full text Traumatic stress Assessment Hopelessness Psychological pain +5

Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.

Journal of Affective Disorders February 15, 2025 Zhan-Ming Shi, Xian-Jun Lan, Qing Chen et al. 6 citations

Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD. Randomized controlled...

DOI: 10.1016/j.jad.2024.11.034 Full text Major depressive disorder Bipolar depression Ect Iv ketamine +6

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.

Journal of Affective Disorders February 1, 2025 Grant Jones, Matthew X. Lowe, Sandeep M. Nayak et al. 12 citations

Psilocybin (a psychoactive compound found in "magic mushrooms" or "shrooms") has been gaining increased attention in research and popular culture as a number of clinical and observational studies have demonstrated that it may have potential for improving mental wellbeing. Relatedly, there has been a substantial uptick in naturalistic (e.g., real-world, non-clinical) psilocybin use in the United...

DOI: 10.1016/j.jad.2024.10.058 Full text Psilocybin Psychedelic medicine Hallucinogenic treatment Racial inequities +7

Effect of ketamine on task-based functional magnetic resonance imaging findings in major depressive disorder: A mini-review.

Journal of Affective Disorders February 1, 2025 Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al. 4 citations

Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...

DOI: 10.1016/j.jad.2024.10.118 Full text Major depressive disorder Mood disorders Task-Based FMRI Ketamine therapy +4

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.

Journal of Affective Disorders January 15, 2025 Sara Ellis, Catherine Bostian, Wendy Feng et al. 23 citations

The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability. This is the first study to evaluate the efficacy and safety of psilocybin in Veterans with severe treatment-resistant depression (TRD). 15 Veterans with severe TRD (major depressive episode failing to respond to ≥5 treatments, or lasting >2 years)...

DOI: 10.1016/j.jad.2024.09.133 Full text Depressive disorder Treatment-resistant depression #depression mental health Mood disorder +7

Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study.

Journal of Affective Disorders January 15, 2025 Fernanda Palhano-Fontes, Patrícia Cavalcanti-Ribeiro, Kaike Thiê da Costa Gonçalves et al. 7 citations

Ketamine has gained prominence as one of the most effective therapeutic options in unipolar treatment-resistant depression (TRD). However, most studies related to the antidepressant action of ketamine used intravenous (IV) or intranasal (IN) administration. The subcutaneous (SC) route of administration is a promising alternative, as it results in plasma levels comparable to IV, causes fewer...

DOI: 10.1016/j.jad.2024.09.141 Full text Treatment-resistant depression Subcutaneous Unipolar depression Depression treatment +3

Brain structural changes underlying clinical symptom improvement following fast-acting treatments in treatment resistant depression.

Journal of Affective Disorders January 15, 2025 Zhiliang Long, Jiao Li, Marco Marino 7 citations

Electroconvulsive therapy (ECT), ketamine infusion (KI), and total sleep deprivation (TSD) are effective and fast in treating patients with treatment-resistant depression (TRD). However, it remains unclear whether the three treatments have the same effect on clinical symptom improvement and have common brain structural mechanisms. The current study included 127 TRD patients and 37 healthy...

DOI: 10.1016/j.jad.2024.09.150 Full text Treatment-resistant depression Electroconvulsive therapy Gray matter volume Ketamine infusion +7

Sniffing out a solution: How emotional body odors can improve mindfulness therapy for social anxiety.

Journal of Affective Disorders January 15, 2025 Cinzia Cecchetto, Elisa Dal Bò, Emma T Eliasson et al. 5 citations

Human body odors (BOs) serve as an effective means of social communication, with individuals exposed to emotional BOs experiencing a partial replication of the sender's affective state. This phenomenon may be particularly relevant in conditions where social interactions are impaired, such as social anxiety. Our study aimed to investigate if emotional human BOs could augment the benefits of...

DOI: 10.1016/j.jad.2024.10.088 Full text Mindfulness Affective symptoms Body odors Human chemosignals +2

Effects of subanesthetic repeated esketamine infusions on memory function and NGF in patients with depression: An open-label study.

Journal of Affective Disorders January 15, 2025 Qiongyao Yang, Yitan Yao, Xiaoping Yuan et al. 3 citations

Subanesthetic ketamine is a rapidly acting antidepressant, yet the effects of ketamine on cognitive function are inconsistent. The primary objective of this study was to explore the effects of esketamine on memory function and plasma levels of nerve growth factor (NGF) in patients with depression. A total of 132 patients with depression completed six intravenous esketamine infusions (0.4 mg/kg)...

DOI: 10.1016/j.jad.2024.09.162 Full text Major depressive disorder Antidepressant Cognition Nerve growth factor +5

The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.

Journal of Affective Disorders January 15, 2025 Jia-Ru Li, Kuo-Tung Chiang, Yu-Chen Kao et al. 1 citation

Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (psilocybin, lysergic acid diethylamide...

DOI: 10.1016/j.jad.2024.10.016 Full text MDMA Psilocybin Psychedelic-therapy Depression-treatment +4

Electroconvulsive therapy combined with esketamine improved depression through PI3K/AKT/GLT-1 pathway.

Journal of Affective Disorders 2025 Xiangyang Zang, Jingting Zhang, Jingping Hu et al. 16 citations

Neuron excitotoxic damage induced by extracellular glutamate accumulation pathologically is one of the main mechanisms of depression. Glutamate transporter-1 (GLT-1) expressed in astrocyte is responsible for glutamate clearance to maintain glutamate balance. Electroconvulsive therapy (ECT) is prevalently recommended for severe depression due to its significant anti-depressant effect. Esketamine...

DOI: 10.1016/j.jad.2024.08.123 Full text Depression Esketamine Electroconvulsive therapy Glutamate transporter +5

Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial.

Journal of Affective Disorders 2025 Qing-Bin Zeng, De-Cheng Zou, Xing-Bing Huang et al. 12 citations

Electroconvulsive therapy (ECT) is a commonly used alternative for treatment-resistant depression (TRD). Although esketamine has a rapid pharmacological antidepressant action, it has not been studied as an ECT anesthetic. The objective of this study was to compare the efficacy and safety of esketamine with propofol when both are used as ECT anesthetic agents. Forty patients with TRD were...

DOI: 10.1016/j.jad.2024.09.038 Full text Esketamine Propofol Electroconvulsive therapy ect Shock therapy +7

Effects of arketamine on depression-like behaviors and demyelination in mice exposed to chronic restrain stress: A role of transforming growth factor-β1.

Journal of Affective Disorders December 15, 2024 Dan Xu, Guilin Liu, Mingming Zhao et al. 21 citations

Chronic restrain stress (CRS) induces depression-like behaviors and demyelination in the brain; however, the relationship between these depression-like behaviors and demyelination remains unclear. Arketamine, the (R)-enantiomer of ketamine, has shown rapid antidepressant-like effects in CRS-exposed mice. We examined whether arketamine can improve both depression-like behaviors and demyelination...

DOI: 10.1016/j.jad.2024.08.222 Full text Arketamine Depression Antidepressant Chronic stress +6

Interventional approaches to treatment resistant depression (DTR) in children and adolescents: A systematic review and meta-analysis.

Journal of Affective Disorders December 15, 2024 Ethan Faries, Landon A Mabe, Ronald L Franzen et al. 13 citations

Major depressive disorder (MDD) is highly prevalent in youth. Conventional treatment paradigms primarily involve selective serotonin reuptake inhibitors (SSRIs) and psychotherapy, yet a significant proportion of this population exhibits treatment-resistant depression (TRD). In adults, interventional therapies like Electroconvulsive Therapy (ECT), repetitive Transcranial Magnetic Stimulation...

DOI: 10.1016/j.jad.2024.08.212 Full text Ketamine Treatment-resistant depression Ect Interventional psychiatry +6

Acceptability, usage, and efficacy of mindfulness apps for college student mental health: A systematic review and meta-analysis of RCTs.

Journal of Affective Disorders December 15, 2024 Liva G Lamontagne, Jennifer L Doty, David C Diehl et al. 11 citations

Preventing anxiety and depression among college students is a pressing public health need. Recent meta-analyses have examined mobile mindfulness interventions in adult populations; however, college students are in a unique developmental stage and institutional setting. We conducted a systematic literature review and meta-analysis of published and unpublished studies in English language on the...

DOI: 10.1016/j.jad.2024.09.014 Full text Anxiety Depression Mindfulness Mental health +2

Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.

Journal of Affective Disorders December 15, 2024 Giacomo d'Andrea, Andrea Miuli, Mauro Pettorruso et al. 6 citations

Treatment-Resistant Depression (TRD) affects almost 30 % of patients with Major Depressive Disorder (MDD). Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD in combination with a Serotonin Specific Reuptake Inhibitor/SSRI or a Serotonin-Norepinephrine Reuptake Inhibitor/SNRI. There is a lack of studies investigating the effectiveness and safety of ESK-NS in combination with...

DOI: 10.1016/j.jad.2024.09.004 Full text Esk-ns Emotional blunting Glutamate Vortioxetine +5

Effects of ketamine on metabolic parameters in depressive disorders: A systematic review.

Journal of Affective Disorders December 15, 2024 Sabrina Wong, Gia Han Le, Rodrigo B. Mansur et al. 3 citations

Persons with Major Depressive Disorder (MDD), notably treatment-resistant depression (TRD), are differentially affected by type 2 diabetes mellitus and associated morbidity. Ketamine is highly efficacious in the treatment of adults living with MDD, notably TRD. Herein, we sought to determine the effect of ketamine on metabolic parameters in animal stress paradigms and human studies. We...

DOI: 10.1016/j.jad.2024.08.208 Full text Glucose homeostasis Insulin Treatment-resistant depression trd Ketamine therapy +4

The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial.

Journal of Affective Disorders December 15, 2024 Rodrigo Machado‐Vieira, Gregory H Jones, Alan C. Courtes et al.

Fatigue is a multidimensional condition that may overlap with depression. Initial studies found that fatigue responds in only a limited way to standard monoaminergic antidepressants and mood stabilizers but does respond positively to intravenous (IV) racemic (R,S)-ketamine (ketamine). However, IV ketamine's use is limited by cost and access barriers. To date, no study has evaluated intranasal...

DOI: 10.1016/j.jad.2024.08.183 Full text Alcohol use disorder Bipolar Ketamine therapy Mental health treatments +3

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.

Journal of Affective Disorders November 15, 2024 Abigail E. Calder, Gregor Hasler 20 citations

Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effects. Measuring side effects is challenging because they are not always easily differentiated from treatment effects or disease symptoms and show high heterogeneity, variable duration and impact, and sensitivity to context. A systematic questionnaire...

DOI: 10.1016/j.jad.2024.08.091 Full text Adverse effects Psychedelics Safety Side effects +5

Papers